Erdafitinib for the treatment of urothelial cancer

L Marandino, D Raggi, P Giannatempo… - Expert review of …, 2019 - Taylor & Francis
Introduction: Fibroblast growth-factor receptor (FGFR) inhibition is a promising strategy of
treatment in urothelial cancer (UC). FGFR3 mutations or fusions (mut/fus) are common in …
被引用次数：25 相关文章

Erdafitinib for the treatment of urothelial cancer.

L Marandino, D Raggi, P Giannatempo… - Expert Review of …, 2019 - europepmc.org
Introduction: Fibroblast growth-factor receptor (FGFR) inhibition is a promising strategy of
treatment in urothelial cancer (UC). FGFR3 mutations or fusions (mut/fus) are common in …

[引用][C] Erdafitinib for the treatment of urothelial cancer

L Marandino, D Raggi, P Giannatempo, E Fare… - EXPERT REVIEW OF …, 2019 - iris.unisr.it
Erdafitinib for the treatment of urothelial cancer IRIS IRIS Home Sfoglia Macrotipologie &
tipologie Autore Titolo Riviste Serie IT Italiano Italiano English English LOGIN 1.IRIS 2.Catalogo …

Erdafitinib for the treatment of urothelial cancer

L Marandino, D Raggi… - Expert review of …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction: Fibroblast growth-factor receptor (FGFR) inhibition is a promising strategy of
treatment in urothelial cancer (UC). FGFR3 mutations or fusions (mut/fus) are common in …